(July 12, 2018) A study involving 58,472 women between 1994 and 2015 concluded that assisted reproductive treatment, or ART, did not lead to an increased risk of ovarian cancer. Originally it was thought that the hormones used in ART would increase ovarian activity, which would in turn increase one’s risk of ovarian cancer. However, data … Continued
(July 2, 2018) Last month the American Society of Clinical Oncology (ASCO) held its annual meeting in Chicago, IL. Thirty nine thousand people from around the world attend to learn about the latest in cancer research. Ovarian cancer survivor and research advocate Annie Ellis attended the meeting and wrote a report highlighting some of the … Continued
(June 29, 2018) Avastin, or bevacizumab, was recently approved by the FDA to be used first with chemotherapy, then by itself, after surgery. A phase III trial studied 1,873 women who had not had any prior treatments for stage III or IV epithelial ovarian, primary peritoneal, or fallopian tube carcinoma. Once the women had undergone … Continued
Name: Sayla H.Hometown: Portland, ORStatus: In treatmentAdvocacy Goal: Oral Parity, Access to Care Sayla was diagnosed earlier last year and is currently in treatment. She’s determined to use her experience to help other women, and is empowered to advocate for women fighting ovarian cancer through OCRA’s Advocate Leader program. Tell us about your ovarian cancer … Continued
Name: Elise D.Hometown: Durham, NHStatus: 13-Year SurvivorAdvocacy Goal: Access to Care Elise feels lucky that she was diagnosed with early-stage ovarian cancer, and being an Advocate Leader allows her to fight for women who may not be able to fight for themselves. Tell us about your ovarian cancer journey. In the summer of 2005, I … Continued
Over 250 ovarian cancer survivors will travel from across the country to attend OCRFA’s Ovarian Cancer National Conference in Washington DC on July 13-15 Reserve your spot today and join our welcoming community of survivors, caregivers and experts for an inspirational weekend packed with empowering information and new friendships. Registration includes: Sign up now to … Continued
(June 11, 2018) OCRFA, who has hosted Super Saturday in the Hamptons for the past 20 years is moving our iconic event to Manhattan. Super September will be held Thursday evening, September 27, and Friday, September 28. According to the New York Post, Page Six, “It’s the end of an era for Super Saturday. The … Continued
(June 6, 2018) OCRFA is pleased to announce we have once again earned a 4-star rating from Charity Navigator, America’s largest independent charity evaluator. This is the highest rating awarded by Charity Navigator, and demonstrates our steady commitment to responsible fiscal management, and to organizational transparency and accountability, as we continue to strive toward a cure for … Continued
Don’t miss your chance to hear top experts speak at the “Ask the Experts” session at OCRFA’s Ovarian Cancer National Conference. Ask the Experts panelists include: We’ve extended our Ask the Experts Q&A session, giving you more time to learn and more time to answer your questions about ovarian cancer research, science and clinical trials. … Continued
(May 18, 2018) Just last month, three of OCRFA’s research advocates attended the 5 day AACR meeting in Chicago, Illinois to learn about new therapies and innovative technology, stay up to date on current projects, and attend lectures from ovarian cancer researchers such as Dr. Anil Sood of MD Anderson and Dr. Dineo Khabele of … Continued
Donate Now It was August of 2001 when I awoke one evening with a stabbing pain in my side that was so serious, I headed straight to the emergency room. I left with a diagnosis of “depression” and a bottle of painkillers. Something inside me – a gut feeling I can’t explain – told me … Continued
(May 4, 2018) JAMA Oncology recently published a study that looked at the risk of breast cancer in BRCA1 carriers who underwent a prophylactic bilateral salpingo-oophorectomy, a surgery that removes both ovaries before any sign of disease, followed by hormone replacement therapy (HRT). Eight hundred and seventy two women were followed for around 7.5 years … Continued
Get email updates about research news, action alerts, and ways to join the fight.
A global, Al-powered ecosystem designed to transform gynecologic cancer research—connecting patients, researchers, and clinicians to accelerate breakthroughs.
Our website uses cookies to ensure you get the best experience. By continuing to use this website, you indicate that you have read and agree to our Terms of Use and Privacy Policy.
